Introduction: We have previously shown modest weight loss with vildagliptin treatment. Since body weight balance is associated with changes in blood pressure (BP) and fasting lipids, we have assessed these parameters following vildagliptin treatment. Methods: Data were pooled from all double-blind, randomized, controlled, vildagliptin monotherapy trials on previously drug-naive patients with type 2 diabetes mellitus who received vildagliptin 50 mg once daily (qd) or twice daily (bid; n=2,108) and wherein BP and fasting lipid data were obtained. Results: Data from patients receiving vildagliptin 50 mg qd or bid showed reductions from baseline to week 24 in systolic BP (from 132.5+0.32 to 129.8+0.34 mmHg; P<0.0001), diastolic BP (from 81.2+0.18 to 79.6+0.19 mmHg; P<0.0001), fasting triglycerides (from 2.00+0.02 to 1.80+0.02 mmol/L; P<0.0001), very low density lipoprotein cholesterol (from 0.90+0.01 to 0.83+0.01 mmol/L; P<0.0001), and low density lipoprotein cholesterol (from 3.17+0.02 to 3.04+0.02 mmol/L; P<0.0001), whereas high density lipoprotein cholesterol increased (from 1.19+0.01 to 1.22+0.01 mmol/L; P<0.001). Weight decreased by 0.48+0.08 kg (P<0.001). Conclusion: This large pooled analysis demonstrated that vildagliptin shows a significant reduction in BP and a favorable fasting lipid profile that are associated with modest weight loss. Keywords: TG, HDL, LDL, body weight DPP-4 inhibitor, GLP-1